Skip navigation
Skip navigation

Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen

Aguilar, J C; Lobaina, Y; Muzio, V; Garcia, D; Penton, E; Iglesias, E; Pichardo, D; Urquiza, D; Rodriguez, D; Silva, Diego; Petrovsky, Nikolai; Guillen, G


There are estimated to be 350 million chronic carriers of hepatitis B infection worldwide. Patients with chronic hepatitis B are at risk of liver cirrhosis with associated mortality because of hepatocellular carcinoma and other complications. An important goal, therefore, is the development of an effective therapeutic vaccine against chronic hepatitis B virus (HBV). A major barrier to the development of such a vaccine is the impaired immune response to HBV antigens observed in the T cells of...[Show more]

CollectionsANU Research Publications
Date published: 2004
Type: Journal article
Source: Immunology and Cell Biology
DOI: 10.1111/j.0818-9641.2004.01278.x


File Description SizeFormat Image
01_Aguilar_Development_of_a_nasal_vaccine_2004.pdf391.86 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  20 July 2017/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator